Skip to the beginning of the images gallery

Cilengitide - ≥98%, high purity , Integrin alpha-V/beta-5 antagonist, CAS No.188968-51-6, Integrin alpha-V/beta-5 antagonist

Moligand™
≥98%

CAS#: 188968-51-6
Formula: C₂₇H₄₀N₈O₇
Molecular Weight: 588.66
PubChem CID: 176873

Item Number

C126639

Grouped product items
SKU	Size	Availability	Price
C126639-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$129.90
C126639-10mg	10mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$220.90
C126639-50mg	50mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$994.90

Potent and selective inhibitor of integrins αvβ3and αvβ5

View related series

integrin αVβ3 Antagonist

Basic Description

Synonyms	Cilengitide\|188968-51-6\|2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid\|EMD 121974\|EMD-121974\|EMD-12192\|EMD121974\|Cyclo(L-arginylglycyl-L-alpha
Specifications & Purity	Moligand™, ≥98%
Biochemical and Physiological Mechanisms	Potent and selective inhibitor of integrinsαvβ3andαvβ5(IC50values are 4.1 and 70 nM, respectively). Exhibits ~10-fold selectivity over gpIIb/IIIa. Increases endothelial monolayer permeability. Also exhibits antiangiogenic activity.
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	ANTAGONIST
Mechanism of action	Integrin alpha-V/beta-5 antagonist
Note	5mg、50mg卖完停产，不再备货
Product Description	Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM, respectively; ~10-fold selectivity against gpIIbIIIa.

Associated Targets

MDM2 Tchem E3 ubiquitin-protein ligase Mdm2 0 Activities

Discover Target: MDM2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MDM4 Tchem Protein Mdm4 0 Activities

Discover Target: MDM4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Discover Target: HDAC6

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGA2B Tclin Integrin alpha-IIb 0 Activities

Discover Target: ITGA2B

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGB3 Tclin Integrin beta-3 0 Activities

Discover Target: ITGB3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGB1 Tclin Integrin beta-1 0 Activities

Discover Target: ITGB1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGAV Tchem Integrin alpha-V 0 Activities

Discover Target: ITGAV

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
INCHI	InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
InChi Key	AMLYAMJWYAIXIA-VWNVYAMZSA-N
Canonical SMILES	CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
Isomeric SMILES	CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
PubChem CID	176873
Molecular Weight	588.66

CAS Registry No.

Wikipedia

PubChem CID

ChEMBL Ligand

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

1 results found

Lot Number	Certificate Type	Date	Item
F1501080	Certificate of Analysis	Dec 08, 2022	C126639

References

1. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE. (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.. Neurosurgery, 48 (1): (151-7). [PMID:11152340]
2. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B et al.. (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.. Int J Cancer, 124 (11): (2719-27). [PMID:19199360]
3. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. (2006) Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.. Neurosurgery, 59 (6): (1304-12; discussion 1312). [PMID:17277694]
4. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS et al.. (2012) A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.. Melanoma Res, 22 (4): (294-301). [PMID:22668797]
5. Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P et al.. (2016) Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.. Oncotarget, 7 (12): (15018-32). [PMID:26918452]
6. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D et al.. (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.. Lancet Oncol, 15 (10): (1100-8). [PMID:25163906]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.